You might also like
Serina Therapeutics, Inc. (SER) is a clinical-stage biotechnology company focused on developing drug product candidates to treat neurological diseases, pain, and other indications. The company utilizes its proprietary POZ (poly(2-oxazoline)) technology platform to enhance the efficacy and safety profiles of therapeutic agents. SER primarily sells drug candidates that are modified using the POZ platform to improve pharmacokinetic profiles.
- Grant Revenues - Derives revenue from grants, primarily from the National Institutes of Health, supporting research and development activities.
- License Revenues - Occasionally earns revenue from license agreements, such as the non-exclusive license agreement with Pfizer for POZ polymer technology in drug delivery formulations.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Balkrishan Simba Gill ExecutiveBoard | Executive Chairman of the Board of Directors | Venture Partner at Flagship Pioneering; Board Member at Foghorn Therapeutics | Balkrishan 'Simba' Gill, Ph.D. is the Executive Chairman at SER since March 24, 2025. He has extensive experience in biotechnology, previously serving in leadership roles including as founding Executive Chair and CEO at other companies. | |
Steve Ledger ExecutiveBoard | Chief Executive Officer | Managing Partner at Form & Fiction Ventures, Inc.; Co-founder and Board Director at Entourage Genomics, Inc. | CEO of Serina Therapeutics since March 2024, previously served as CFO from June 2021 to March 2024. | View Report → |
Gregory S. Curhan Executive | Chief Financial Officer | Partner at FLG Partners, LLC; CFO at Curevo Vaccines | Gregory S. Curhan has served as CFO of Serina Therapeutics, Inc. since August 2024 through his capacity as a partner at FLG Partners, LLC. He also holds active roles as CFO at Curevo Vaccines, demonstrating extensive experience in financial management. | |
Randall Moreadith Executive | Chief Development Officer | Randall Moreadith, M.D., Ph.D., is a seasoned life sciences executive currently serving as Chief Development Officer at SER since March 2024. He previously served as President and CEO and was a member of the Board of Directors from September 2010 to March 2024. | ||
Srini Tenjarla Executive | Senior Vice President of CMC and Formulation | Srini Tenjarla serves as Senior Vice President of CMC and Formulation at SER since July 15, 2024, bringing over 30 years of industry experience and previous leadership roles at Takeda and Shire. | ||
Gregory H. Bailey Board | Legacy Serina Board Member | Executive Chairman of Juvenescence; Board Director at Manx Financial Group, plc; Board Director at BioHaven Ltd.; Board Director at SalvaRx Group, plc; Board Director at Portage Biotech, Inc. | Gregory H. Bailey, M.D., joined SER's Legacy Serina Board in March 2023 and serves as a Class III director with his current term expiring in 2026. He practiced emergency medicine for 10 years before transitioning into executive leadership roles, including his current position as Executive Chairman of Juvenescence. | |
Jay Venkatesan Board | Board Director | Board Director at Elicio Therapeutics | Jay Venkatesan is a board director at SER, serving as the Audit Committee Chair and a member of the Nominating and Corporate Governance Committee since February 12, 2025. He has extensive expertise in biotechnology investment and strategic growth from his leadership roles at other companies, including his current role as Board Director at Elicio Therapeutics. | |
Karen J. Wilson Board | Board of Directors | Board Director at Connect Biopharma Holdings Limited; Board Director at Elicio Therapeutics, Inc.; Board Director at LAVA Therapeutics NV | Karen J. Wilson is a seasoned finance expert with over 30 years of experience in the life sciences sector, currently serving on the Board of Directors, as Chair of the Compensation Committee, and as an Audit Committee Member at Serina Therapeutics since January 14, 2025. Previously, she held significant finance roles at Jazz Pharmaceuticals and other companies. | |
Richard Marshall Board | Director | CEO of Juvenescence | Richard Marshall serves as a Director and has been a Board member at SER since March 2024, while also serving on its Nominating and Corporate Governance Committee. | |
Stephen Brannan Board | Member of the Board of Directors | Stephen Brannan, M.D. is a board member at Serina Therapeutics, appointed on May 22, 2025, and also serves on the Compensation Committee. He brings over three decades of expertise in neuroscience drug development and has held senior leadership roles at Karuna Therapeutics, Takeda, Novartis, and others. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Pfizer | Non-exclusive license | License | $3.0 million in December 2023 (~95% of FY 2023 total revenue) |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
AgeX Therapeutics, Inc. | 2024 | The acquisition was executed as a reverse recapitalization merger under an Agreement and Plan of Merger dated August 29, 2023, with share conversion at a ratio of 0.97682654 per Legacy Serina share and the assumption of outstanding stock options and warrants. The strategic rationale was to reposition the combined entity as a clinical-stage biotechnology company leveraging Legacy Serina’s proprietary POZ drug delivery technology, with additional considerations such as warrant dividends and listing on NYSE American. |
Recent press releases and 8-K filings for SER.
- Net loss of $4.8 million (−$0.49 per share) in Q1 2025 versus $15.0 million (−$5.38 per share) in Q1 2024, on operating expenses of $5.9 million.
- Cash and cash equivalents of $4.3 million at March 31, 2025, with an additional $5 million received in April, providing runway through Q3 2025.
- $15 million in equity financing secured since late 2024, including a $10 million investment from JuvVentures and a $5 million private placement in April 2025.
- Phase 1b trial of SER-252 for advanced Parkinson’s disease on track for first patient dosing in Q4 2025.
- Board strengthened with the addition of Karen J. Wilson and Dr. Jay Venkatesan during Q1 2025.
- On April 25, 2025, Serina Therapeutics entered into a Capital on Demand™ Sales Agreement with JonesTrading, enabling an “at-the-market” offering of up to $13.27 million of its common stock under its effective Form S-3 registration.
- The Company will pay commissions of up to 3% of gross proceeds and reimburse JonesTrading’s legal fees up to $50,000 in connection with the ATM program.
- On April 8, 2025, Serina issued 962,250 shares of Series A Convertible Preferred Stock at $5.18 per share in a private placement.
- Serina’s authorized capital includes 40 million common shares and 5 million preferred shares, with its board authorized to issue preferred stock without further stockholder approval.
- The updated description of capital stock in Exhibit 4.1 supersedes any prior descriptions in the Company’s SEC filings.
- Serina reported $56 thousand in 2024 revenues versus $3.2 million in 2023 and recorded a net loss of $11.1 million (–$1.51/share) compared to 2023 net income of $5.3 million ($2.36/share).
- Cash and equivalents were $3.7 million as of December 31, 2024, with a projected runway through Q2 2025.
- In November 2024 and January 2025, Serina secured $10 million in equity financing from JuvVentures and in December 2024 sold its UniverXome subsidiary, eliminating $11.2 million of debt.
- The company added Karen J. Wilson and Dr. Jay Venkatesan to its board and advanced its partnership with Enable Injections toward a Phase 1b trial of SER-252 in late 2025.